In recent years, several studies have identified LRRK2 mutations or dysregulation of its expression in various types of human malignancies including thyroid cancer [54], intrahepatic cholangiocarcinoma [55], lung cancer [56, 57], and renal carcinoma [58]. Here, LRRK2 is linked to lung carcinoma.